X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4392) 4392
Magazine Article (20) 20
Book Chapter (15) 15
Newspaper Article (14) 14
Newsletter (4) 4
Publication (4) 4
Book / eBook (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3560) 3560
dabigatran (3415) 3415
warfarin (2203) 2203
anticoagulants - therapeutic use (1939) 1939
anticoagulants (1901) 1901
rivaroxaban (1795) 1795
atrial fibrillation (1493) 1493
male (1425) 1425
female (1342) 1342
aged (1263) 1263
administration, oral (1233) 1233
stroke (1224) 1224
atrial fibrillation - drug therapy (1223) 1223
apixaban (1099) 1099
anticoagulants - adverse effects (1071) 1071
stroke - prevention & control (1010) 1010
dabigatran etexilate (946) 946
anticoagulants - administration & dosage (907) 907
prevention (865) 865
benzimidazoles - therapeutic use (857) 857
middle aged (849) 849
atrial fibrillation - complications (844) 844
cardiac & cardiovascular systems (838) 838
hemorrhage - chemically induced (794) 794
beta-alanine - analogs & derivatives (792) 792
warfarin - therapeutic use (785) 785
atrial-fibrillation (775) 775
hematology (763) 763
peripheral vascular disease (739) 739
venous thromboembolism (725) 725
pharmacology & pharmacy (719) 719
thromboembolism (716) 716
risk factors (703) 703
treatment outcome (698) 698
aged, 80 and over (655) 655
dabigatran - therapeutic use (596) 596
management (580) 580
beta-alanine - therapeutic use (564) 564
pyrazoles - therapeutic use (564) 564
pyridones - therapeutic use (564) 564
risk (557) 557
medicine, general & internal (554) 554
stroke prevention (554) 554
safety (550) 550
anticoagulation (539) 539
antithrombins - therapeutic use (539) 539
stroke - etiology (526) 526
cardiac arrhythmia (522) 522
therapy (507) 507
thrombin (499) 499
abridged index medicus (478) 478
bleeding (461) 461
medicine & public health (451) 451
oral anticoagulants (447) 447
benzimidazoles - adverse effects (443) 443
pyridines - therapeutic use (439) 439
analysis (423) 423
direct thrombin inhibitor (422) 422
drug therapy (415) 415
care and treatment (413) 413
hemorrhage (401) 401
patients (399) 399
thiophenes - therapeutic use (390) 390
warfarin - adverse effects (390) 390
morpholines - therapeutic use (389) 389
thrombosis (386) 386
dabigatran - adverse effects (379) 379
vitamin k - antagonists & inhibitors (379) 379
cardiology (372) 372
antithrombins - adverse effects (361) 361
rivaroxaban - therapeutic use (351) 351
efficacy (343) 343
retrospective studies (341) 341
adult (337) 337
benzimidazoles - administration & dosage (335) 335
blood coagulation - drug effects (335) 335
venous thromboembolism - prevention & control (321) 321
beta-alanine - adverse effects (315) 315
thromboembolism - prevention & control (312) 312
pharmacokinetics (311) 311
antithrombotic therapy (309) 309
mortality (302) 302
edoxaban (300) 300
dosage and administration (298) 298
risk assessment (295) 295
double-blind (294) 294
venous thromboembolism - drug therapy (293) 293
fibrillation (291) 291
internal medicine (290) 290
surgery (284) 284
factor xa inhibitors (283) 283
direct oral anticoagulants (282) 282
randomized controlled trials as topic (274) 274
anticoagulants - pharmacology (273) 273
metaanalysis (272) 272
warfarin - administration & dosage (270) 270
clinical trials (269) 269
enoxaparin (269) 269
reversal (261) 261
aspirin (258) 258
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4217) 4217
German (99) 99
French (75) 75
Spanish (69) 69
Russian (17) 17
Japanese (14) 14
Portuguese (14) 14
Hungarian (9) 9
Czech (8) 8
Danish (8) 8
Italian (8) 8
Swedish (7) 7
Finnish (4) 4
Polish (4) 4
Dutch (3) 3
Turkish (3) 3
Norwegian (2) 2
Arabic (1) 1
Chinese (1) 1
Korean (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Summary Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct... 
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | ANDEXANET-ALPHA | VITAMIN-K ANTAGONISTS | rivaroxaban | apixaban | ATRIAL-FIBRILLATION | antidotes | IN-VITRO | ANTIIDIOTYPIC ANTIBODIES | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2018, Volume 16, Issue 9, pp. 1891 - 1894
...) monotherapy for at least 3–6 months, owing to the lack of cancer‐specific data regarding the use of these agents . Both recent emerging data from clinical practice... 
PROPHYLAXIS | THERAPY | THROMBOSIS | SAFETY | DISEASE | PREVENTION | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | GUIDELINE | Recurrence | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Neoplasms - complications | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Multicenter Studies as Topic | Neoplasms - blood | Dalteparin - therapeutic use | Observational Studies as Topic | Venous Thrombosis - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Administration, Oral | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Patient Acceptance of Health Care | Pulmonary Embolism - etiology | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Pulmonary Embolism - drug therapy | Pyridones - therapeutic use | Hemorrhage - chemically induced | Care and treatment | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Cancer | Anticoagulants
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 16, pp. 1513 - 1524
..., and such findings have prompted efforts to seek new therapeutic strategies. 10 – 15 Two new promising approaches have emerged to reduce the risk of bleeding among patients... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics
Journal Article
The American journal of medicine, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 24, pp. 2888 - 2899
... are at least as effective as warfarin, are safer, do not require routine monitoring, and are simpler to use (1–5) . In 2013, NOACs accounted for 62% of new prescriptions... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | apixaban | stroke | edoxaban | renal dialysis | CARDIAC & CARDIOVASCULAR SYSTEMS | APPENDAGE CLOSURE | PLATELET-AGGREGATION | SAFETY | PHARMACOKINETICS | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | HEMODIALYSIS-PATIENTS | NONVALVULAR ATRIAL-FIBRILLATION | STAGE RENAL-DISEASE | WARFARIN USE | Pyrazoles - therapeutic use | Dabigatran - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Renal Insufficiency, Chronic - therapy | Kidney - metabolism | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Glomerular Filtration Rate | Pyridones - pharmacokinetics | Atrial Fibrillation - drug therapy | Anticoagulants - therapeutic use | Creatinine - urine | Warfarin - pharmacokinetics | Kidney Failure, Chronic - therapy | Rivaroxaban - pharmacokinetics | Kidney Failure, Chronic - complications | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Hemorrhage - chemically induced | Renal Dialysis | Stroke (Disease) | Medical colleges | Care and treatment | Continuing medical education | Warfarin | Chronic kidney failure | Atrial fibrillation | Mortality | Medical care | Quality management | Urine | Confidence intervals | Disease prevention | Anticoagulants | Stroke | Hemodialysis | Kidney diseases | Metabolism | Drug dosages
Journal Article
The American journal of medicine, ISSN 0002-9343, 2015, Volume 128, Issue 12, pp. 1300 - 1305.e2
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2017, Volume 130, Issue 9, pp. 1015 - 1023
Abstract Renal impairment increases risk of stroke and systemic embolic events and bleeding in patients with atrial fibrillation. Direct oral anticoagulants... 
Internal Medicine | Atrial fibrillation | Direct oral anticoagulants | THERAPEUTIC RANGE | SAFETY | RIVAROXABAN | GLOMERULAR-FILTRATION-RATE | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | WARFARIN | ORAL ANTICOAGULANTS | CHRONIC KIDNEY-DISEASE | CREATININE CLEARANCE | CLINICAL-OUTCOMES | Dabigatran - adverse effects | Pharmaceutical Research - statistics & numerical data | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Anticoagulants - administration & dosage | Humans | Pharmaceutical Research - standards | Warfarin - adverse effects | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Warfarin - administration & dosage | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Thiazoles - adverse effects | Factor Xa Inhibitors - administration & dosage | Warfarin - therapeutic use | Pyridones - administration & dosage | Pyridines - adverse effects | Rivaroxaban - adverse effects | Hemorrhage - etiology | Pharmaceutical Research - methods | Renal Insufficiency - complications | Embolism - etiology | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Pyridines - administration & dosage | Embolism - complications | Risk Assessment | Administration, Oral | Atrial Fibrillation - drug therapy | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Stroke - etiology | Pyridones - therapeutic use | Pyridones - adverse effects | Therapeutic Equivalency | Stroke (Disease) | Drugstores | Health care industry | Warfarin | Pharmacy
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 11/2017, Volume 2017, Issue 11, p. CD011373
.... The conventional antithrombotic prophylaxis agent warfarin is often prescribed for the prevention of stroke, but risk of bleeding necessitates regular therapeutic monitoring... 
Kidney disease | Anticoagulants | Pyridines | Renal Insufficiency, Chronic | Stroke | Warfarin | Administration, Oral | Pyrazoles | Pyridones | Chronic kidney disease | Dabigatran | Hemorrhage | Embolism | Randomized Controlled Trials as Topic | Arrythmias | Rivaroxaban | Cardiovascular risk management | Antithrombins | Thiazoles | Heart & circulation | General management | Medicine General & Introductory Medical Sciences | Atrial Fibrillation | EAST-ASIAN PATIENTS | MEDICINE, GENERAL & INTERNAL | J-ROCKET AF | XA NEXT-GENERATION | TRANSIENT ISCHEMIC ATTACK | AF-TIMI 48 | VITAMIN-K ANTAGONISM | RIVAROXABAN VS. WARFARIN | LY RANDOMIZED EVALUATION | PERIPHERAL ARTERY-DISEASE | SEVERE RENAL IMPAIRMENT | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Warfarin - adverse effects | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - adverse effects | Warfarin - therapeutic use | Pyridines - adverse effects | Rivaroxaban - adverse effects | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Hemorrhage - epidemiology | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Antithrombins - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects
Journal Article